Healthcare / Drug Manufacturers - Specialty & GenericShenzhen
$8.30
+0.10 (+1.22%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-62.3M · quality 55.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
53/100
C
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$4.8B
P/E
36.1x
↑EV/EBITDA
18.3x
↑ROE
4.1%
↑Gross Margin
45.8%
↓Debt/Equity
0.23
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+16.3%
FCF CAGR
—
FCF margin
-5.2%
FCF / Net income
-0.67x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.21B · net income $92.7M · FCF $-62.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.21B | $1.21B | $983.6M | $890.7M | $765.9M |
| Net Income | $92.7M | $92.7M | $13.7M | $-71.8M | $11.3M |
| EBITDA | $245.6M | $245.6M | $152.3M | $36.4M | $110.5M |
| EPS | 0.18 | 0.18 | 0.03 | -0.15 | 0.02 |
| Gross Margin | 45.8% | 45.8% | 47.7% | 47.0% | 55.4% |
| Operating Margin | 8.5% | 8.5% | 6.6% | -0.0% | 4.1% |
| Net Margin | 7.7% | 7.7% | 1.4% | -8.1% | 1.5% |
| Balance Sheet | |||||
| Debt/Equity | 0.23 | 0.23 | 0.48 | 0.48 | 0.36 |
| Current Ratio | 2.39 | 2.39 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-62.3M | $-62.3M | $61.6M | $-86.1M | $25.0M |
| Returns | |||||
| ROE | 4.1% | 4.1% | 0.8% | -4.3% | 0.6% |
| Valuation | |||||
| P/E | 36.09 | 36.09 | 197.33 | — | 326.50 |
| EV/EBITDA | 18.31 | 18.31 | 9.51 | 197.22 | 7.25 |
| P/B | 1.89 | 1.89 | 0.54 | 4.33 | 0.52 |
| Growth & Yield | |||||
| Revenue Growth | 22.5% | 22.5% | 10.4% | 16.3% | — |
| EPS Growth | 500.0% | 500.0% | 120.0% | -850.0% | — |
| Dividend Yield | 0.6% | 0.6% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
59.9%
EPS terminal req.
$0.74
Spread vs growth
440.1%
5Y implied EPS CAGR
37.7%
EPS terminal req.
$0.89
Spread vs growth
462.3%
10Y implied EPS CAGR
23.1%
EPS terminal req.
$1.44
Spread vs growth
476.9%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+24.4%
Start / end P/E
223.3x → 46.1x
EPS bridge
0.03 → 0.18
Residual
-396.8%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.